FDA 483 - Parag Kalyani, M.D. - July 01, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Parag Kalyani, MBBS, MD, Clinical Investigator in Pune, India, identified significant failures in conducting a bioequivalence/bioavailability clinical study according to Good Clinical Practices. The inspection revealed widespread issues including inadequate case histories, numerous data discrepancies, missing and manipulated study documentation, and insufficient adverse event reporting. These findings raise serious concerns about the integrity and reliability of the clinical trial data.
ID · 44f92f7e-8c78-4f6e-9fc0-3e32c121cfa6